Yeah that’s a good point. Our trial design seems a lot smarter. The other thing which I keep coming back to is the eligibility criteria for starting uPCR. DMX has shown in our previous trials to have a more significant reduction on patients with higher starting uPCR. And obviously a higher reduction in uPCR leads to more improvement to kidney function and reduction of eGFR slope. So this all bodes well for us hopefully.
Note - a big disclaimer here for anyone that read my earlier posts - but I think for some reason I referred to uPCR as “uPVC”. Not sure if this was auto spell correct or if I’m dyslexic! But please just substitute these terms when reading….hopefully everyone knew what I meant.
Dimerix (ASX: DXB) Discussion Thread, page-151
Add DXB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
46.5¢ |
Change
0.010(2.20%) |
Mkt cap ! $252.8M | |||
| Open | High | Low | Value | Volume |
| 44.5¢ | 47.5¢ | 44.0¢ | $763.5K | 1.674M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 6 | 70169 | 46.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 46.5¢ | 38543 | 5 |
View Market Depth
| Last trade - 10.44am 31/05/2024 (20 minute delay) ? |
|
|||||
|
Last
47.0¢ |
Change
0.010 ( 3.73 %) |
||||
| Open | High | Low | Volume | ||
| 44.5¢ | 47.5¢ | 44.5¢ | 1102565 | ||
| Last updated 11.06am 31/05/2024 ? | |||||
| DXB (ASX) Chart |